JP2012519728A5 - - Google Patents

Download PDF

Info

Publication number
JP2012519728A5
JP2012519728A5 JP2011553553A JP2011553553A JP2012519728A5 JP 2012519728 A5 JP2012519728 A5 JP 2012519728A5 JP 2011553553 A JP2011553553 A JP 2011553553A JP 2011553553 A JP2011553553 A JP 2011553553A JP 2012519728 A5 JP2012519728 A5 JP 2012519728A5
Authority
JP
Japan
Prior art keywords
fatty acid
preconcentrate
mixtures
acid
dha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011553553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012519728A (ja
JP6176894B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/000824 external-priority patent/WO2010103404A1/en
Publication of JP2012519728A publication Critical patent/JP2012519728A/ja
Publication of JP2012519728A5 publication Critical patent/JP2012519728A5/ja
Application granted granted Critical
Publication of JP6176894B2 publication Critical patent/JP6176894B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011553553A 2009-03-09 2010-03-09 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用 Active JP6176894B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US15861309P 2009-03-09 2009-03-09
US61/158,613 2009-03-09
US24263009P 2009-09-15 2009-09-15
US61/242,630 2009-09-15
US25429309P 2009-10-23 2009-10-23
US25429109P 2009-10-23 2009-10-23
US61/254,293 2009-10-23
US61/254,291 2009-10-23
PCT/IB2010/000824 WO2010103404A1 (en) 2009-03-09 2010-03-09 Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015253166A Division JP6723009B2 (ja) 2009-03-09 2015-12-25 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用

Publications (3)

Publication Number Publication Date
JP2012519728A JP2012519728A (ja) 2012-08-30
JP2012519728A5 true JP2012519728A5 (enExample) 2013-07-25
JP6176894B2 JP6176894B2 (ja) 2017-08-09

Family

ID=42727856

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011553553A Active JP6176894B2 (ja) 2009-03-09 2010-03-09 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用
JP2015253166A Active JP6723009B2 (ja) 2009-03-09 2015-12-25 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用
JP2018018093A Pending JP2018090600A (ja) 2009-03-09 2018-02-05 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用
JP2020018504A Active JP7199389B2 (ja) 2009-03-09 2020-02-06 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015253166A Active JP6723009B2 (ja) 2009-03-09 2015-12-25 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用
JP2018018093A Pending JP2018090600A (ja) 2009-03-09 2018-02-05 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用
JP2020018504A Active JP7199389B2 (ja) 2009-03-09 2020-02-06 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用

Country Status (17)

Country Link
US (6) US9532963B2 (enExample)
EP (4) EP3915554A1 (enExample)
JP (4) JP6176894B2 (enExample)
KR (3) KR101841756B1 (enExample)
CN (3) CN110538148A (enExample)
AU (1) AU2010222648B2 (enExample)
BR (1) BRPI1009431A2 (enExample)
CA (2) CA3065860A1 (enExample)
CO (1) CO6501136A2 (enExample)
EA (1) EA022028B1 (enExample)
ES (3) ES2881885T3 (enExample)
IL (1) IL215043A (enExample)
MX (1) MX2011009503A (enExample)
NZ (1) NZ595204A (enExample)
PH (1) PH12019500030A1 (enExample)
SG (1) SG174314A1 (enExample)
WO (3) WO2010103402A1 (enExample)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010222648B2 (en) * 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
MX2011011517A (es) 2009-04-29 2012-06-19 Amarin Corp Plc Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
LT2443246T (lt) 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
JP5951489B2 (ja) * 2009-10-16 2016-07-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC 組成物
WO2011048493A1 (en) * 2009-10-23 2011-04-28 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
JP5827625B2 (ja) 2009-10-29 2015-12-02 アカスティ ファーマ インコーポレイテッド 濃縮治療用リン脂質組成物
PE20130491A1 (es) 2009-12-30 2013-05-02 Basf Pharma Callanish Ltd Proceso simulado de separacion cromatografica de lecho movil para la purificacion de acidos grasos poliinsaturados
CA2993690C (en) 2010-01-19 2022-03-22 Dsm Ip Assets B.V. Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof
US11236351B2 (en) 2010-05-17 2022-02-01 Dow Agrosciences Llc Production of DHA and other LC PUFAs in plants
EP2613767A4 (en) * 2010-09-08 2014-03-19 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin
AR082930A1 (es) * 2010-09-08 2013-01-16 Pronova Biopharma Norge As Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
EP2613766A4 (en) * 2010-09-08 2014-04-09 Pronova Biopharma Norge As COMPOSITIONS COMPRISING AN OIL MIXTURE CONSISTING OF FATTY ACIDS COMPRISING EPA AND DHA AS FREE ACID, SURFACTANT AND STATIN
NZ610705A (en) * 2010-11-05 2014-10-31 Pronova Biopharma Norge As Methods of treatment using lipid compounds
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en) * 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US20120302639A1 (en) * 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
WO2012112531A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
CA2827561A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd)
JP2014505729A (ja) * 2011-02-16 2014-03-06 ピヴォタル セラピューティクス インコーポレイテッド コレステロールの低減および心血管事象の低減のための、コレステロール吸収阻害剤(アゼチジノン)およびω3脂肪酸(EPA、DHA、DPA)
EP2675446A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
US8952000B2 (en) * 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8697676B2 (en) 2011-06-15 2014-04-15 Ronald E Rosedale Omega-3 fatty acid nutriceutical composition and optimization method
US8865685B2 (en) * 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
ES2857173T3 (es) * 2011-07-21 2021-09-28 Dsm Ip Assets Bv Aceites microbianos enriquecidos en ácidos grasos poliinsaturados
EA035287B1 (ru) 2011-07-21 2020-05-25 ДСМ АйПи АССЕТС Б.В. Микроорганизмы, продуцирующие эйкозапентаеновую кислоту, композиции, содержащие жирные кислоты, и способы их получения и применения
TW201307553A (zh) * 2011-07-26 2013-02-16 Dow Agrosciences Llc 在植物中生產二十二碳六烯酸(dha)及其他長鏈多元不飽和脂肪酸(lc-pufa)之技術
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013072767A1 (en) * 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
SG11201403805WA (en) 2012-01-06 2014-08-28 Omthera Pharmaceuticals Inc Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
WO2013142482A1 (en) 2012-03-20 2013-09-26 Particle Dynamics International, Llc Gelling agent-based dosage form
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
AU2013240427B2 (en) * 2012-03-30 2017-08-03 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US20150132389A1 (en) * 2012-03-30 2015-05-14 Sancilio & Company, Inc. Omega-3 Fatty Acid Ester Compositions
US9480651B2 (en) * 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US20150125529A1 (en) * 2012-03-30 2015-05-07 Sancilio & Company, Inc. Omega-3 Fatty Acid Ester Compositions
US10898458B2 (en) * 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
AR095182A1 (es) 2012-05-07 2015-09-30 Omthera Pharmaceuticals Inc Composiciones de estatinas y ácidos grasos omega-3
DE202013012875U1 (de) * 2012-05-14 2021-01-15 Nippon Suisan Kaisha, Ltd. Zusammensetzung, umfassend hochungesättigte Fettsäure oder hochungesättigten Fettsäureethylester mit verringerten Umweltschadstoffen
US20140194512A1 (en) * 2012-06-17 2014-07-10 Matinas Biopharma, Inc. Compositions comprising docosapentaenoic acid and methods of use
EP2861227A4 (en) * 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
CN103015230B (zh) * 2012-11-27 2015-04-01 广州嘉德乐生化科技有限公司 一种单硬脂酸甘油酯和聚氧乙烯醚脂肪酸皂的组合物
EP2928462A4 (en) * 2012-12-06 2016-06-01 Matinas Biopharma Inc METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
KR102213143B1 (ko) * 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
EP2968246A4 (en) * 2013-03-13 2016-08-03 Matinas Biopharma Inc OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US20140322314A1 (en) * 2013-04-29 2014-10-30 Matinas Biopharma, Inc. Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
JPWO2015008849A1 (ja) 2013-07-18 2017-03-02 持田製薬株式会社 ω3脂肪酸の自己乳化組成物
CN111888343A (zh) 2013-07-18 2020-11-06 持田制药株式会社 ω-3脂肪酸的自乳化组合物
WO2015011724A2 (en) * 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP3118186B1 (fr) 2013-12-11 2022-02-09 Novasep Process Installation chromatographique de production d acides gras polyinsatures
PT3626806T (pt) 2013-12-20 2024-07-31 Mara Renewables Corp Métodos para recuperar óleo de microrganismos
WO2015104464A1 (fr) 2014-01-07 2015-07-16 Novasep Process Procédé de purification d'acides aminés aromatiques
US10143674B2 (en) * 2014-01-28 2018-12-04 Fresenius Kabi Deutschland Gmbh Composition comprising EPA and DHA triglycerides for parenteral administration
EP3129002A4 (en) 2014-04-09 2017-11-08 Nanoceutica Laboratories Pvt. Ltd Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base
CN106687113B (zh) * 2014-06-06 2021-09-03 海洋原料公司 ω-3组合物、剂型及使用方法
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
RU2712142C2 (ru) * 2014-11-05 2020-01-24 Эбботт Лабораторис Гмбх Способы получения композиций с улучшенным профилем безопасности, содержащих панкреатин, и композиции, пригодные для фармацевтического применения
CN105614638A (zh) * 2014-11-28 2016-06-01 深圳市前海安测信息技术有限公司 Dha纳米乳及其制备方法和其在健康保健饮品中的应用
US10561627B2 (en) * 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US11007161B1 (en) * 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
WO2016117057A1 (ja) 2015-01-21 2016-07-28 持田製薬株式会社 ω3脂肪酸の自己乳化組成物
CN107922308B (zh) * 2015-06-02 2024-11-12 内斯托尔株式会社 新型甘油三酯及其用途
RU2655803C2 (ru) * 2016-03-10 2018-05-29 АД Смарт, СИА Фармацевтическая композиция для профилактики и лечения атеросклероза
AU2017232554B2 (en) * 2016-03-16 2020-05-14 Golden Omega Norway As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
CN106072611A (zh) * 2016-06-20 2016-11-09 威海百合生物技术股份有限公司 一种含不饱和脂肪酸的多相稀释组合物
GB201611920D0 (en) * 2016-07-08 2016-08-24 Astrazeneca Ab Pharmaceutical compositions
AU2017301077B2 (en) * 2016-08-12 2022-07-07 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
WO2018054265A1 (zh) * 2016-09-20 2018-03-29 张碧婷 亲水性脂类组合物的包装组合物,其制备及调配方法和应用
WO2018116093A1 (en) 2016-12-22 2018-06-28 MARA Renewables Corporation Methods for producing biomass rich in dha, palmitic acid and protein using a eukaryotic microorganism
CN107048405A (zh) * 2017-03-03 2017-08-18 武汉锶博睿医药技术有限公司 脂肪酸组件微胶囊及其制备方法
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
ES3038235T3 (en) 2018-11-30 2025-10-10 Evonik Operations Gmbh Preparation comprising a dispersion of phospholipids and fatty acid salts
US20220175710A1 (en) 2019-04-18 2022-06-09 Akershus Universitetssykehus Hf Combination therapy
KR102096391B1 (ko) * 2019-10-11 2020-04-06 (주)아이엠디팜 액상결정 구조체를 형성하는 오메가-3-지방산 조성물
CN110584084A (zh) * 2019-10-17 2019-12-20 广州白云山汉方现代药业有限公司 一种乳化稳定剂及含该乳化稳定剂的营养乳液
CN114980973A (zh) 2019-11-12 2022-08-30 阿马里纳药物爱尔兰有限公司 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
AU2021245403A1 (en) 2020-04-03 2022-11-24 MARA Renewables Corporation Microbial oils with high levels of omega-3 fatty acids
CN113827547A (zh) * 2020-06-23 2021-12-24 南京清普生物科技有限公司 一种缓释制剂组合物
CN111729125B (zh) * 2020-07-31 2022-10-04 陕西佰傲再生医学有限公司 骨止血材料
JP2021008518A (ja) * 2020-10-21 2021-01-28 持田製薬株式会社 ω3脂肪酸の自己乳化組成物
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
JP2025502795A (ja) * 2021-12-29 2025-01-28 中国科学院上海薬物研究所 Epa-eeナノ脂質組成物、その製剤、調製方法及び使用
KR20230161551A (ko) * 2022-05-18 2023-11-28 부광약품 주식회사 제제학적으로 안정성이 향상된 연질 캡슐

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (enExample) 1971-05-24 1978-05-01
GB2033745B (en) * 1978-05-26 1983-08-17 Wellcome Found Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
AU552068B2 (en) 1981-09-21 1986-05-22 Asama Chemical Co. Ltd. Preservation of edible oils
ATE55056T1 (de) 1982-12-09 1990-08-15 Advanced Drug Tech Einfach absorbierbare fettsaeureemulsionen.
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4843095A (en) * 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5532002A (en) * 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
AU633959B2 (en) 1989-08-17 1993-02-11 Cortecs Limited Pharmaceutical formulations
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5501077A (en) * 1994-05-27 1996-03-26 Springwell Dispensers, Inc. Thermoelectric water chiller
JPH0889167A (ja) 1994-09-27 1996-04-09 Nippon Oil & Fats Co Ltd 多価不飽和脂肪酸含有醗酵乳の製造方法
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
DE19608137A1 (de) * 1996-03-02 1997-09-04 Meyer Lucas Gmbh & Co Lipid-Zubereitungen für diätetische Zwecke
WO1999029335A1 (en) 1997-12-05 1999-06-17 Chong Kun Dang Corp. Pharmaceutical composition containing cyclosporin
WO1999029300A1 (en) 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations
ATE497384T1 (de) 1997-12-10 2011-02-15 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
AU3843999A (en) * 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20050037065A1 (en) 1999-05-27 2005-02-17 Drugtech Corporation Nutritional formulations
ES2246769T3 (es) * 2000-05-22 2006-03-01 Pro Aparts - Investimentos E Consultoria Lda Composicion de acidos grasos que contiene al menos 80% en peso de epa y dha o sus derivados y su uso farmaceutico.
EP1279400A1 (en) * 2001-07-25 2003-01-29 Target Hit sa Modifying the fatty acid composition of cell membranes of organs and tissues
KR100441167B1 (ko) 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
ITMI20020269A1 (it) 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
GB0210212D0 (en) 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
ITMI20022511A1 (it) 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
WO2004056370A1 (en) 2002-12-20 2004-07-08 Pronova Biocare As Use of a fatty acid composition for treatment of male infertility
SE0303513D0 (sv) * 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0413729D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413730D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
AU2005271413A1 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
US20090030077A1 (en) * 2004-08-06 2009-01-29 Transform Pharmaceuticals Inc. Novel Fenofibrate Formulations and Related Methods of Treatment
KR20070052760A (ko) * 2004-08-06 2007-05-22 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 페노피브레이트 제제 및 관련된 치료방법
EP1789031A2 (en) * 2004-08-18 2007-05-30 Ace ApS Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
US20060051462A1 (en) * 2004-09-03 2006-03-09 Wang Jimmy X Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
GB0428384D0 (en) * 2004-12-24 2005-02-02 Sla Pharma Ag Eicosapentaenoic acid
CA2594781A1 (en) * 2005-01-24 2006-07-27 Pronova Biocare As Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases
US20060211763A1 (en) 2005-03-08 2006-09-21 Abdel Fawzy Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof
EP1790339B1 (en) 2005-07-08 2014-06-04 Mochida Pharmaceutical Co., Ltd. Composition for prevention of occurrence of cardiovascular event
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
CA2634139C (en) 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
JP2009525992A (ja) 2006-02-10 2009-07-16 スポーツコム デンマーク アプス コーティングを施した錠剤、その製造方法、及び関連する使用
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
JP2009544702A (ja) 2006-07-21 2009-12-17 リライアント・ファーマシューティカルズ・インコーポレイテッド 抵抗性高血圧症の治療に使用するオメガ−3脂肪酸
JP2009544701A (ja) * 2006-07-21 2009-12-17 リライアント・ファーマシューティカルズ・インコーポレイテッド オメガ3脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用
US7676518B2 (en) 2006-08-16 2010-03-09 Sap Ag Clustering for structured data
WO2008088415A1 (en) * 2006-10-18 2008-07-24 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids for reduction of lp-pla2 levels
CA2677670C (en) * 2007-03-20 2010-08-03 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
PL2124973T3 (pl) 2007-03-23 2015-10-30 Novartis Ag Kompozycja zawierająca kwasy tłuszczowe omega-3 oraz zamaskowane lub powleczone sole miedzi
US20080261896A1 (en) 2007-04-11 2008-10-23 Sinphar Pharmaceutical Co., Ltd. Testosterone generating and metabolizing enhancer
CA2692394A1 (en) 2007-07-06 2009-01-15 Seth J. Baum Fatty acid compositions and methods of use
US8370627B2 (en) 2008-01-04 2013-02-05 University Of Yamanashi Confidential communication method
UA102477C2 (en) 2008-01-10 2013-07-10 Такеда Фармасьютикал Компани Лимитед Capsule composition
US20100062057A1 (en) 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
US20100130608A1 (en) 2008-10-01 2010-05-27 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
AU2010222648B2 (en) * 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
JP5951489B2 (ja) 2009-10-16 2016-07-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC 組成物
WO2011048493A1 (en) 2009-10-23 2011-04-28 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture

Similar Documents

Publication Publication Date Title
JP2012519728A5 (enExample)
JP7199389B2 (ja) 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用
JP6835664B2 (ja) 脂肪酸油混合物の被覆型カプセル剤および錠剤
JP2013508348A5 (enExample)
JP2013537186A (ja) 脂肪酸油混合物と遊離脂肪酸とスタチンとを含む組成物
US20230218560A1 (en) Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
TW201311294A (zh) 含脂肪酸油混合物、界面活性劑與司它汀(statin)的組成物